Referencia número: HY-13519

TRAM-34

29 Cited Publications

Revisión del cliente

Based on 29 publication(s) in Google Scholar

TRAM-34 is a highly selective blocker of intermediate-conductance calcium-activated K⁺ channel (IKCa1) (K_d=20 nM).

Para uso exclusivo en investigación. No vendemos a pacientes.

Pureza: 99.78%
No. CAS: 289905-88-0
Fòrmula: C₂₂H₁₇ClN₂
Peso molecular:344.84

Almacenamiento:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

TRAM-34 Chemical Structure

No. CAS: 289905-88-0

Tamaño

Precio

Stock

Cantidad

Amount: USD 0.00

* Seleccione Cantidad antes de agregar artículos.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Actividad biológica
- Descripciòn
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (29)
Solvente y solubilidad
- In Vitro
- In Vivo
Protocolo
Pureza y Documentación
Referencias
Help & FAQs
Classifications
Bioz

Actividad biológica

Descripciòn

TRAM-34 is a highly selective blocker of intermediate-conductance calcium-activated K⁺ channel (IKCa1) (K_d=20 nM).

IC₅₀ & Target

Kd: 20 nM (IKCa1)^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
COS-7	IC₅₀	0.02 μM Compound: TRAM-34	Inhibition of human cloned IK1 expressed in african green monkey COS7 cells by whole cell patch clamp assay Inhibition of human cloned IK1 expressed in african green monkey COS7 cells by whole cell patch clamp assay	[PMID: 19282171]
HaCaT	EC₅₀	40 μM Compound: TRAM-34	Inhibition of human HaCaT cell proliferation after 48 hrs Inhibition of human HaCaT cell proliferation after 48 hrs	[PMID: 19282171]
PBMC	EC₅₀	0.025 μM Compound: TRAM-34	Immunosuppressant activity in human effector memory T cells of PBMC assessed as inhibition of anti-CD3 antibody-induced cell proliferation by ELISA in presence of 5 uM Kv1.3-blocker PAP1 Immunosuppressant activity in human effector memory T cells of PBMC assessed as inhibition of anti-CD3 antibody-induced cell proliferation by ELISA in presence of 5 uM Kv1.3-blocker PAP1	[PMID: 19282171]

In Vitro

TRAM-34 selectively blocks the IKCa1 current (K_d=25 nM), TRAM-34 also blocks IKCa1 currents in human T84 colonic epithelial cells with equivalent potency (K_d=22 nM). TRAM-34 inhibits the cloned and the native IKCa1 channel in human T lymphocytes with a K_d of 20-25 nM and is 200- to 1,500-fold selective over other ion channels. The dose-response curve reveals a K_d of 20±3 nM and a Hill coefficient of 1.2 with 1 μM calcium in the pipette^[1].
TRAM-34, a specific inhibitor of K_Ca 3.1 channels increased or decreased cell proliferation depending on the concentration. At intermediate concentrations (3-10 μM) TRAM-34 increased cell proliferation, whereas at higher concentrations (20-100 μM) TRAM-34 decreased cell proliferation. The enhancement of cell proliferation caused by TRAM-34 is blocked by the oestrogen receptor antagonists ICI182,780 and Tamoxifen. TRAM-34 also increases progesterone receptor mRNA expression, decreased oestrogen receptor-α mRNA expression and reduced the binding of radiolabelled oestrogen to MCF-7 oestrogen receptor, in each case mimicking the effects of 17β-oestradiol^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Mice (n=5) injected intravenously with a single dose of TRAM-34 (0.5 mg/kg; 29 μM) appeared clinically normal during the 7-day study. The body-weight data of the TRAM-34-treated group (day 1:17.8 g; day 7: 27.0 g) are similar to control mice injected with the vehicle (day 1: 17.4 g; day 7: 23.4 g). Collectively, data from these limited toxicity studies suggest that TRAM-34 is not acutely toxic at ≈500-1,000 times the channel-blocking dose^[1].
Treatment with TRAM-34 results in a significant reduction in hematoxylin & eosin (H&E) defined lesion area with the mean infarct size being reduced from 22.6±3.6% in the controls (n=8) to 11.3±2.8% in rats treated with 10 mg/kg TRAM-34 (n=6, mean±s.e.m., P=0.039) and to 8.1±1.9% in rats treated with 40 mg/kg TRAM-34 (n=8; P=0.004). The treatment also tended to reduce brain shrinkage. However, the results are only statistically significant with 40 mg/kg TRAM-34 (P=0.013), but not for the 10 mg/kg group (P=0.11)^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

No. CAS 289905-88-0
Appearance Solid
Peso molecular 344.84
Fòrmula C₂₂H₁₇ClN₂
Color White to off-white
SMILES

ClC1=CC=CC=C1C(N2N=CC=C2)(C3=CC=CC=C3)C4=CC=CC=C4
Envío

Room temperature in continental US; may vary elsewhere.

Almacenamiento

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (29)

All In Vivo Efficacy StudyBio/Physico-chemical Assay

Sort by:

Journal Impact Factor

Nat Immunol

Early methionine availability attenuates T cell exhaustion. [Abstract]

2025 Aug;26(8):1384-1396. PMID: 40702340

TRAM-34 purchased from MedChemExpress. Usage Cited in: Nat Immunol. 2025 Aug;26(8):1384-1396. [Abstract]

Tumor growth of B16-OVA tumors in Rag1^−/− mice after transfer of OT-I CD8⁺ T cells activated in 0.1 mM or 0.03 mM Met with either DMSO or 1 μM TRAM-34 for 30 min and cultured for 24 h (n = 5 mice per group).

TRAM-34 purchased from MedChemExpress. Usage Cited in: Nat Immunol. 2025 Aug;26(8):1384-1396. [Abstract]

Representative plot of Fluo-8 AM analysis of Ca²⁺ flux in CD8⁺ T cells activated by IgG crosslinking anti-CD3 and anti-CD28 in Ca²⁺-free Ringer solution with either 0.1 mM or 0.03 mM Met and treated with either DMSO or 1 μM TRAM-34 (n = 2 mice/group).

TRAM-34 purchased from MedChemExpress. Usage Cited in: Nat Immunol. 2025 Aug;26(8):1384-1396. [Abstract]

NFAT1 quantification (nuclear to total cell ratio) in OT-I CD8⁺ T cells activated for 30 min with anti CD3/28 Dynabeads in 0.03 mM Met (left) or 0.1 mM Met (right) in 0.5, 1 or 2 μM TRAM-34 (each circle=one cell, n = 27–45 cells/group).

TRAM-34 purchased from MedChemExpress. Usage Cited in: Nat Immunol. 2025 Aug;26(8):1384-1396. [Abstract]

Schematic design for OT-I T cell activation in 0.1 or 0.03 mM Met, treated with DMSO or TRAM-34 for 30 min, followed by washing and culturing in 0.1 mM Met plus SIINFEKL (2.5 ng/ml) for 24 h before injection into B16-OVA tumour-bearing Rag1^−/− mice.
Nat Commun

Kir2.1-mediated membrane potential promotes nutrient acquisition and inflammation through regulation of nutrient transporters. [Abstract]

2022 Jun 21;13(1):3544. PMID: 35729093
Haematologica

Red blood cell Gardos channel (KCNN4): the essential determinant of erythrocyte dehydration in hereditary xerocytosis. [Abstract]

2017 Oct;102(10):e415-e418. PMID: 28619848

TRAM-34 purchased from MedChemExpress. Usage Cited in: Haematologica. 2017 Oct;102(10):e415-e418. [Abstract]

RBC osmotic resistance was assessed in Ca²⁺ containing medium after 18 hours' incubation at 37℃. Different drugs blocking KCNN4, TRAM-34 or Senicapoc, were added to the incubating medium.
Can J Cardiol

KCa3.1 promotes the migration of macrophages from epicardial adipose tissue to induce vulnerability to atrial fibrillation during rapid pacing. [Abstract]

2024 Aug 13:S0828-282X(24)00916-4. PMID: 39147322
Life Sci

Regulatory role of Piezo1 channel in endothelium-dependent hyperpolarization-mediated vasorelaxation of small resistance vessels and its anti-inflammatory action. [Abstract]

2024 Jan 1:336:122326. PMID: 38056769
Eur J Pharmacol

Novel mechanisms of metformin-induced vasorelaxation of mesenteric arterioles via endothelium-dependent hyperpolarization to treat murine colitis. [Abstract]

2025 Sep 15:1003:177900. PMID: 40617384
J Mol Cell Cardiol

Elevated KCa3.1 expression by angiotensin II via the ERK/NF-κB pathway contributes to atrial fibrosis. [Abstract]

2025 May:202:133-143. PMID: 40122157
J Inflamm Res

KCa3.1 Inhibition of Macrophages Suppresses Inflammatory Response Leading to Endothelial Damage in a Cell Model of Kawasaki Disease. [Abstract]

2021 Mar 5;14:719-735. PMID: 33727847
Cell Calcium

Drug repurposing DMSO from an old solvent to a new candidate for the treatment of colitis and sepsis in male mice. [Abstract]

2026 May 23:136:103155. PMID: 42235215
Cell Calcium

Activation of TRPM8 promotes K+ secretion in rat epididymal epithelium. [Abstract]

2026 Mar:134:103117. PMID: 41539212
Cell Calcium

Mechanosensitive Piezo1 channel in rat epididymal epithelial cells promotes transepithelial K+ secretion. [Abstract]

2022 Jun;104:102571. PMID: 35314382
Heliyon

N,N,N',N'-Tetrakis(2-pyridylmethyl)ethylenediamine induces endothelium-dependent hyperpolarization-mediated vasorelaxation via store-operated calcium entry mechanism in healthy and intestinal inflammatory mice. [Abstract]

2024 Jul 6;10(14):e33994. PMID: 39108891
Heliyon

SK4 calcium-activated potassium channels activated by sympathetic nerves enhances atrial fibrillation vulnerability in a canine model of acute stroke. [Abstract]

2020 May 7;6(5):e03928. PMID: 32420493
Mol Med Rep

M2 macrophage‑derived exosomes alleviate KCa3.1 channel expression in rapidly paced HL‑1 myocytes via the NF‑κB (p65)/STAT3 signaling pathway. [Abstract]

2024 Apr;29(4):55. PMID: 38334149
Cardiovasc Ther

KCa3.1 Promotes Proinflammatory Exosome Secretion by Activating AKT/Rab27a in Atrial Myocytes during Rapid Pacing. [Abstract]

2023 Mar 30:2023:3939360. PMID: 37035755
Int J Med Sci

Blockade of SK4 channels suppresses atrial fibrillation by attenuating atrial fibrosis in canines with prolonged atrial pacing. [Abstract]

2022 Nov 7;19(14):1995-2007. PMID: 36483596
Cell Biol Int

Inhibition of intermittent calcium-activated potassium channel (SK4) attenuates Ang II-induced hypertrophy of human-induced stem cell-derived cardiomyocytes via targeting Ras-Raf-MEK1/2-ERK1/2 and CN-NFAT signaling pathways. [Abstract]

2023 Feb;47(2):480-491. PMID: 36273427
Front Cardiovasc Med

Inhibition of KCa3.1 Channels Suppresses Atrial Fibrillation via the Attenuation of Macrophage Pro-inflammatory Polarization in a Canine Model With Prolonged Rapid Atrial Pacing. [Abstract]

2021 May 31:8:656631. PMID: 34136541
J Interv Card Electrophysiol

Role of intermediate-conductance calcium-activated potassium channels in atrial fibrillation in canines with rapid atrial pacing. [Abstract]

2021 Mar;60(2):247-253. PMID: 32248426
Clin Exp Pharmacol Physiol

Indole-3-Propionic Acid Improves Vascular Function in High-Fat Diet-Induced Obese Mice via eNOS. [Abstract]

2025 Nov;52(11):e70081. PMID: 41057979
Biochem Biophys Res Commun

Glucose transports in the ileum: mechanism, regulation and physiological role of ileal glucose absorption. [Abstract]

2025 Sep 19:785:152676. PMID: 41005286
Physiol Rep

Calcium-sensing receptor regulates intestinal dipeptide absorption via Ca2+ signaling and IKCa activation. [Abstract]

2020 Jan;8(1):e14337. PMID: 31960592
bioRxiv

2026 Feb 20.
Res Sq

2025 Nov 12.
Traditional Medicine Research

2026;11(2):11.
bioRxiv

An early, novel arginine methylation of KCa3.1 attenuates subsequent T cell exhaustion. [Abstract]

2024 Nov 20:2024.05.09.593421. PMID: 38798680
Res Sq

2024 Jun 11.
bioRxiv

2024 May 14.
Research Square Print

September 14th, 2022.

Solvente y solubilidad

In Vitro:

DMSO : 25 mg/mL (72.50 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.8999 mL

14.4995 mL

28.9990 mL

5 mM

0.5800 mL

2.8999 mL

5.7998 mL

10 mM

0.2900 mL

1.4499 mL

2.8999 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Calculadora de molaridad

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculadora de dilución

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (6.03 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2.08 mg/mL (6.03 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (6.03 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 20% SBE-β-CD in Saline

Solubility: 5 mg/mL (14.50 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocolo

Kinase Assay^[2]

MCF-7 cell protein (250 µg) is incubated at room temperature for 2 h in TEDG buffer in the presence of 0.1 nM [2,4,6,7,16,17-³H(N)]-oestradiol ([³H]-E2) (110 Ci/mmol) in a total final volume of 500 µL. Non-specific binding is assessed in the presence of a 100-fold excess of non-radioactive E2. TRAM-34 and E2 standards are diluted in phenol red-free 5% DCC-FBS MEM containing supplements before being added to the cytosolic protein. A vehicle control comprised of 5% DCC-FBS MEM containing supplements with 0.7% DMSO. To separate ER-bound [³H]-E2 from unbound [³H]-E2, 250 µL of hydroxylapatite (HAP, 60% in TEDG buffer) is added, the mixture is vortexed every 5 min over 15 min and centrifuged at 1000×g for 10 min. The HAP-[³H]-E2-ER complex is washed with TEDG buffer, centrifuged and the wash step repeated. To elute [³H]-E2 from the HAP-[³H]-E2-ER complex, 500 µL of 100% ethanol is added and the mixture then incubated for 15 min and centrifuged at 1034×g for 10 min. The separated [³H]-E2 is removed and added to 2 mL of scintillation fluid. Radioactivity is quantified using a Beckman LS 5000TA scintillation counter. Competition of [³H]-E2 with TRAM-34 is assayed in quadruplicate on four independent protein extractions. An apparent dissociation constant of 0.135±0.034 nM (n=3) and a maximum binding capacity of 48.3±5.4 fmol/mg (n=3) are determined by Scatchard analysis^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[1]^[3]

Mice^[1]
Five CF-1BR mice (17-19 g) are injected intravenously with a single 1.0-ml dose of 0.5 mg/kg TRAM-34 (in mammalian Ringer solution with 1% ethanol and 2.5% BSA). Five control mice are injected with an equal volume of the vehicle. Mice are observed for adverse effects immediately after dosing, at 4 h after injection and daily for 7 days.
Rats^[3]
Adult male Wistar rats weighing 160 to 180 g are used. Rats receive TRAM-34 at 10 mg/kg, 40 mg/kg or vehicle (Miglyol 812 neutral oil at 1 μL/g) twice daily intraperitoneally for 7 days starting 12 hours after reperfusion. Neurological deficits are scored according to a 4-score test and a tactile and proprioceptive limb-placing test as follows: (1) 4-score test (higher score for more severe neurological deficits): 0=no apparent deficit; 1=contralateral forelimb is consistently flexed during suspension by holding the tail; 2=decreasing grip ability on the contralateral forelimb while tail pulled; 3=spontaneous movement in all directions but circling to contralateral side when pulled by the tail; 4=spontaneous contralateral circling or depressed level of consciousness. (2) 14-score limb-placing test (lower score for more severe neurological deficits): proprioception, forward extension, lateral abduction, and adduction are tested with vision or tactile stimuli. For visual limb placing, rats are held and slowly moved forward or lateral toward the top of a table. Normal rats placed both forepaws on the tabletop. Tactile forward and lateral limb placing are tested by lightly contacting the table edge with the dorsal or lateral surface of a rat's paw while avoiding whisker contact and covering the eyes to avoid vision.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Pureza y Documentación

Select Batch:

Pureza: 99.98%

Assay: 99.98%

ee.: 99.98%

Ficha de datos (289 KB)
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Korean - KR (392 KB)
- Portuguese - PT (392 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instrucciones de manejo (2659 KB)

Referencias

[1]. Wulff H, et al. Design of a potent and selective inhibitor of the intermediate-conductance Ca2+-activated K+ channel, IKCa1: a potential immunosuppressant. Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):8151-6. [Content Brief]

[2]. Roy JW, et al. The intermediate conductance Ca2+-activated K+ channel inhibitor TRAM-34 stimulates proliferation of breast cancer cells via activation of oestrogen receptors. Br J Pharmacol. 2010 Feb 1;159(3):650-8. [Content Brief]

[3]. Chen YJ, et al. The KCa3.1 blocker TRAM-34 reduces infarction and neurological deficit in a rat model of ischemia/reperfusion stroke. J Cereb Blood Flow Metab. 2011 Dec;31(12):2363-74. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.8999 mL	14.4995 mL	28.9990 mL	72.4974 mL
	5 mM	0.5800 mL	2.8999 mL	5.7998 mL	14.4995 mL
	10 mM	0.2900 mL	1.4499 mL	2.8999 mL	7.2497 mL
	15 mM	0.1933 mL	0.9666 mL	1.9333 mL	4.8332 mL
	20 mM	0.1450 mL	0.7250 mL	1.4499 mL	3.6249 mL
	25 mM	0.1160 mL	0.5800 mL	1.1600 mL	2.8999 mL
	30 mM	0.0967 mL	0.4833 mL	0.9666 mL	2.4166 mL
	40 mM	0.0725 mL	0.3625 mL	0.7250 mL	1.8124 mL
	50 mM	0.0580 mL	0.2900 mL	0.5800 mL	1.4499 mL
	60 mM	0.0483 mL	0.2417 mL	0.4833 mL	1.2083 mL

Keywords

TRAM-34

29 Cited Publications

100 mg Obtener un presupuesto

Subscribe to the

MedChemExpress

Newsletter

Nombre del producto:
Referencia número:
Cantidad:
MCE Japan Authorized Agent:

Nombre del producto:
No. CAS:
Species:
Pureza:
Cantidad:

TRAM-34

Membrane Transporter/Ion Channel Compound Library

Anti-Alzheimer's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Potassium Channel Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Highly Selective Inhibitors Library

Ion Channel Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

RNA Binding Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) TRAM-34

Actividad biológica

Chemical Information

Publications (29)

Solvente y solubilidad

Protocolo

Pureza y Documentación

Referencias

Help & FAQs

Complete Stock Solution Preparation Table

TRAM-34

Membrane Transporter/Ion Channel Compound Library

Anti-Alzheimer's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Potassium Channel Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Highly Selective Inhibitors Library

Ion Channel Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

RNA Binding Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) TRAM-34

Actividad biológica

Chemical Information

Publications (29)

Solvente y solubilidad

Protocolo

Pureza y Documentación

Referencias

Help & FAQs

Complete Stock Solution Preparation Table

TRAM-34 Related Classifications

HY-13519 Related Classifications